Treating the Adult Patient: First Line Therapy

  • Andrew S. deLemosEmail author


First-line therapy for autoimmune hepatitis (AIH) centers around initiation of predniso(lo)ne followed by the introduction of azathioprine to maintain a biochemical remission. Combination therapy during induction with subsequent tapering of steroids with the intent of maintaining remission with azathioprine monotherapy is the goal. A majority of patients with AIH are capable of attaining a remission with first-line therapy and can be cautiously considered for withdrawal of therapy following 3 years of therapy and after at least 2 years of normal transaminase and IgG levels. Relapse following tapering or after discontinuation of therapy is highly likely, and therefore requires close monitoring and timely resumption of therapy. Individualizing treatment to achieve a balance between maximizing the benefits of therapy while limiting toxicities is the foundation of first-line therapy for AIH.


Steroids Prednisone Azathioprine Treatment Management 


  1. 1.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.CrossRefGoogle Scholar
  2. 2.
    De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut. 1978;19(6):510–3.CrossRefGoogle Scholar
  3. 3.
    Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29(6):816–23.CrossRefGoogle Scholar
  4. 4.
    Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62.CrossRefGoogle Scholar
  5. 5.
    Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40(158):159–85.CrossRefGoogle Scholar
  6. 6.
    Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63(5):820–33.CrossRefGoogle Scholar
  7. 7.
    Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53(1):191–8.CrossRefGoogle Scholar
  8. 8.
    Schramm C, Weiler-Normann C, Wiegard C, Hellweg S, Muller S, Lohse AW. Treatment response in patients with autoimmune hepatitis. Hepatology. 2010;52(6):2247–8.CrossRefGoogle Scholar
  9. 9.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102(5):1005–12.CrossRefGoogle Scholar
  10. 10.
    Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8(4):781–4.CrossRefGoogle Scholar
  11. 11.
    Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333(15):958–63.CrossRefGoogle Scholar
  12. 12.
    Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, et al. Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769–75.CrossRefGoogle Scholar
  13. 13.
    Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2018;68(4):754–63.CrossRefGoogle Scholar
  14. 14.
    Thalen A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittelforschung. 1979;29(11):1687–90.PubMedGoogle Scholar
  15. 15.
    Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206.CrossRefGoogle Scholar
  16. 16.
    Manns MP, Jaeckel E, Taubert R. Budesonide in autoimmune hepatitis: the right drug at the right time for the right patient. Clin Gastroenterol Hepatol. 2018;16(2):186–9.CrossRefGoogle Scholar
  17. 17.
    Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260–7. e1.CrossRefGoogle Scholar
  18. 18.
    Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9(12):2681–5.CrossRefGoogle Scholar
  19. 19.
    Efe C, Ozaslan E, Kav T, Purnak T, Shorbagi A, Ozkayar O, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. 2012;11(5):330–4.CrossRefGoogle Scholar
  20. 20.
    Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612–21.CrossRefGoogle Scholar
  21. 21.
    Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13(7):996–1003.CrossRefGoogle Scholar
  22. 22.
    Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61(4):876–82.CrossRefGoogle Scholar
  23. 23.
    Anastasiou OE, Dogan-Cavus B, Kucukoglu O, Baba H, Kahraman A, Gerken G, et al. Corticosteroid therapy improves the outcome of autoimmune hepatitis-induced acute liver failure. Digestion. 2018;98(2):104–11.CrossRefGoogle Scholar
  24. 24.
    Tan P, Marotta P, Ghent C, Adams P. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int. 2005;25(4):728–33.CrossRefGoogle Scholar
  25. 25.
    Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24(8):1197–205.CrossRefGoogle Scholar
  26. 26.
    Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99(8):1510–6.CrossRefGoogle Scholar
  27. 27.
    Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140(7):1980–9.CrossRefGoogle Scholar
  28. 28.
    Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51(1):161–7.CrossRefGoogle Scholar
  29. 29.
    Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35(4):890–7.CrossRefGoogle Scholar
  30. 30.
    Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3(5):685–9.CrossRefGoogle Scholar
  31. 31.
    van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–7.CrossRefGoogle Scholar
  32. 32.
    Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015;62(3):642–6.CrossRefGoogle Scholar
  33. 33.
    Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2(5):410–7.CrossRefGoogle Scholar
  34. 34.
    Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol. 1995;23(3):351–4.PubMedGoogle Scholar
  35. 35.
    Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46(2):149–54.CrossRefGoogle Scholar
  36. 36.
    Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008;6(6):654–60; quiz 04.CrossRefGoogle Scholar
  37. 37.
    Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol. 2002;37(4):441–7.CrossRefGoogle Scholar
  38. 38.
    Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 2006;51(5):968–75.CrossRefGoogle Scholar
  39. 39.
    Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110(1):271–4.CrossRefGoogle Scholar
  40. 40.
    Dhaliwal HK, Anderson R, Thornhill EL, Schneider S, McFarlane E, Gleeson D, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology. 2012;56(4):1401–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Hepatology, Carolinas Medical Center-Atrium HealthCharlotteUSA

Personalised recommendations